Dyne Therapeutics, Inc.: Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights | - Additional Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Anticipated in the Second Half of 2024 - WALTHAM, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Dyne... ► Artikel lesen |
Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer | WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for... ► Artikel lesen |
Dyne Therapeutics Appoints John Cox As CEO To Succeed Joshua Brumm | WASHINGTON (dpa-AFX) - Dyne Therapeutics, Inc. (DYN) said on Monday that it has appointed John Cox as Chief Executive Officer with immediate effect to succeed Joshua Brumm, who has decided to... ► Artikel lesen |
SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates | - Achieved $21.0 million in OGSIVEO® (nirogacestat) net product revenue in the first quarter - - Received validation from the EMA for MAA of nirogacestat for the treatment of adults with desmoid tumors... ► Artikel lesen |
SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN | STAMFORD, Conn., March 04, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced... ► Artikel lesen |
SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors | Application based on Phase 3 DeFi trial in which nirogacestat significantly improved progression-free survival and objective response rate compared to placebo, with rapid and sustained improvements... ► Artikel lesen |
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, May 03, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing... ► Artikel lesen |
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing... ► Artikel lesen |
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, March 01, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing... ► Artikel lesen |